Atopic dermatitis (AD), also known as eczema, is one of the most common inflammatory skin disorders worldwide, with an increasing incidence in the past few decades. In recent years, research on the pathophysiology of AD has highlighted the role of skin barrier dysfunction, cutaneous and systemic immune abnormalities, and the role of the microbiome in the development of this condition. An understanding of the underlying causes of AD has led to the development of new targeted therapies and improved methods of treatment for this challenging and chronic disease.
Our Atopic Dermatitis THRIVE program is an online CME tool that aims to provide clinicians with new strategies to improve standards of care for patients with AD. Click on the links below to learn more about best practices for the diagnosis and assessment of AD, clinical profiles of biologic agents for AD, and how to select treatment options.
This activity is provided by Med Learning Group.
Supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.